Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?

Michal Sternschuss*, Nir Peled, Aaron M. Allen, Elizabeth Dudnik, Ofer Rotem, Noga Kurman, Omer Gal, Hiba Reches, Alona Zer

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience